Effect of psychomotor therapy on negative symptoms and cognitive function of patients with stable schizophrenia

doi:10.3969/j.issn.1674-8115.2022.01.011

Abstract

Abstract: Objective

·To explore the effect of psychomotor therapy on negative symptoms and cognitive function of patients with stable schizophrenia.

Methods

·A random number table was used to divide 64 stable schizophrenia patients from Shanghai No.1 Civil Mental Health Center into a study group and a control group. The control group was given routine treatment, nursing and daily rehabilitation, and the study group increased psychomotor therapy on this basis. Both groups were intervened for 10 weeks, and the patients in the two groups were evaluated by the Positive and Negative Symptom Scale (PANSS), Mini Mental State Examination (MMSE), and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) before and after the intervention.

Results

·Thirty patients in the study group and the control group completed the observation. The repeated-measures analysis of variance (ANOVA) showed that after 10 weeks of intervention, the score of PANSS negative symptom subscale and PANSS total score were lower than those of the control group (all P=0.000), while the scores of MMSE and RBANS were higher than those of the control group (P=0.008, P=0.000). After 10 weeks, the negative symptom subscale score and PANSS total score of the study group were lower than those before the study (all P=0.000), while the MMSE and RBANS scores were higher than those before the study (all P=0.000).

Conclusion

·Psychomotor therapy can improve the negative symptoms and cognitive function of patients with stable schizophrenia.

Key words: psychomotor therapy, schizophrenia, negative symptom, cognitive function

CLC Number:

R749.3

Ruping LU, Hui GAO, Linna JIANG, Xiaoya CHEN, Hong PENG, Hui SHEN, Qing FAN. Effect of psychomotor therapy on negative symptoms and cognitive function of patients with stable schizophrenia[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 77-81.

Figures/Tables 2

TrendMD

References 24

1	PENNINGTON M, MCCRONE P. The cost of relapse in schizophrenia[J]. Pharmacoeconomics, 2017, 35(9): 921-936.
2	刘东玮, 周郁秋, 李国华. 社会支持与精神分裂症残疾: 自尊与心理韧性的链式中介作用[J]. 中国临床心理学杂志, 2019, 27(1): 78-82.
3	邵权威, 李柏. 精神运动疗法在改善士兵体能恢复中的应用[J]. 解放军医院管理杂志, 2015, 22(2): 165-166,180.
4	学报编辑部. 中法医学论坛"精神运动康复的现在与未来"在上海交通大学医学院附属瑞金医院举行[J]. 上海交通大学学报(医学版), 2014, 34(12): 1795.
5	学报编辑部. 中-法精神运动康复学科建设研讨会成功举行[J]. 上海交通大学学报(医学版), 2018, 38(12): 1483.
6	陈雪莲, 孙福刚, 周海文. 精神运动康复应用于精神病人社区康复的可行性研究[J]. 心电图杂志(电子版), 2018, 7(2): 234-236.
7	PESSO A. Psychomotor therapy: an interview with Pesso[J]. FNIB, 1981, 59(2): 22-23.
8	GERBER D, BURGER R, RISCH M, et al. What is psychomotor therapy? What are psychomotor disorders?[J]. Ther Umsch, 1981, 38(4): 367-370.
9	KAY S R, FISZBEIN A, OPLER L A. The positive and negative syndrome scale (PANSS) for schizophrenia[J]. Schizophr Bull, 1987, 13(2): 261-276.
10	张明园, 瞿光亚. 痴呆和Alzheimer病的患病率研究[J]. 上海精神医学, 1989, 7(3):153-160.
11	RANDOLPH C, TIERNEY M C, MOHR E, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity[J]. J Clin Exp Neuropsychol, 1998, 20(3): 310-319.
12	沈渔邨. 精神病学[M]. 5版. 北京: 人民卫生出版社, 2009: 516.
13	王莉. 情志疗法联合精神运动康复用于精神分裂症患者的效果观察[J]. 中国基层医药, 2020, 27(17): 2154-2156.
14	刘群, 王莉, 张振, 等. 中医情志疗法联合精神运动康复在精神分裂症患者中的应用[J]. 中国医学创新, 2020, 17(18): 77-81.
15	KNAPEN J, VAN D E VLIET P, VAN COPPENOLLE H, et al. Improvements in physical fitness of non-psychotic psychiatric patients following psychomotor therapy programs[J]. J Sports Med Phys Fit, 2003, 43(4): 513-522.
16	VANCAMPFORT D, PROBST M, KNAPEN J, et al. Body-directed techniques on psychomotor therapy for people with schizophrenia: a review of the literature[J]. Tijdschr Psychiatr, 2011, 53(8): 531-541.
17	TSAPAKIS E M, DIMOPOULOU T, TARAZI F I. Clinical management of negative symptoms of schizophrenia: an update[J]. Pharmacol Ther, 2015, 153: 135-147.
18	BUTCHER I, BERRY K, HADDOCK G. Understanding individuals' subjective experiences of negative symptoms of schizophrenia: a qualitative study[J]. Br J Clin Psychol, 2020, 59(3): 319-334.
19	王琼, 吴中文, 耿丽, 等. 老年痴呆患者基于精神运动康复学理论的干预[J]. 护理学杂志, 2021, 36(3): 1-4.
20	MONDRAGÓN-MAYA A, RAMOS-MASTACHE D, ROMÁN P D, et al. Social cognition in Schizophrenia,unaffected relatives and ultra-high risk for psychosis:what do we currently know?[J]. Actas Esp Psiquiatr, 2017, 45(5):218-226.
21	张颖, 王若梅, 李刚. 精神分裂症认知功能损害的研究进展[J]. 中国慢性病预防与控制, 2021, 29(2): 158-160.
22	KAUFMAN G B, ARONOFF G M. The use of psychomotor therapy in the treatment of chronic pain[J]. Psychother: Theory Res Pract, 1983, 20(4): 449-456.
23	VANCOPPENOLLE H U, PETER V, KNAPEN J U, et al. Fitnesstraining as psychomotor therapy in depressive patients[J]. Journal of Chinese Integrative Medicine, 1995, 5(5):585-587.
24	BACÚROVÁ E. Use of psychomotor therapy in psychiatric institutions[J]. Ceskoslovenska Psychiatr, 1985, 81(1): 15-19.

Project	Research group （n=32）	Control group （n=32）	t value	P value
Age/year	57.34±6.87	58.47±6.89	-0.654	0.515
Course of disease/year	32.72±6.07	32.75±6.34	-0.020	0.984
Length of stay/year	13.72±7.37	13.09±6.83	0.352	0.726
Years of education/year	10.00±1.97	10.59±2.15	-1.152	0.254
Dosage/mg	321.88±124.39	310.94±122.96	0.354	0.725

Project	Research group （n=32）	Control group （n=32）	t value	P value
Age/year	57.34±6.87	58.47±6.89	-0.654	0.515
Course of disease/year	32.72±6.07	32.75±6.34	-0.020	0.984
Length of stay/year	13.72±7.37	13.09±6.83	0.352	0.726
Years of education/year	10.00±1.97	10.59±2.15	-1.152	0.254
Dosage/mg	321.88±124.39	310.94±122.96	0.354	0.725

Item	Group	n	Point of time		Time		Group		Time × Group
Item	Group	n	Before intervention （0 week）/score	After intervention（10 week）/score	F value	P value	F value	P value	F value	P value
PANSS： positive	Research group	30	11.40±4.65	11.10±4.24	3.976	0.051	0.010	0.920	0.131	0.718
	Control group	30	11.33±5.71	10.90±5.81
PANSS： negative	Research group	30	23.90±5.01	18.20±4.24	82.129	0.000	4.901	0.031	86.063	0.000
	Control group	30	23.60±4.62	23.67±4.81
PANSS： commonly	Research group	30	31.40±6.12	29.70±5.72	17.452	0.000	0.523	0.473	1.652	0.204
	Control group	30	32.20±7.29	31.30±6.90
PANSS： total score	Research group	30	66.70±12.19	59.00±11.31	52.905	0.000	1.229	0.272	27.234	0.000
	Control group	30	67.13±14.21	65.87±13.95
MMSE	Research group	30	27.07±2.16	28.93±1.08	55.596	0.000	4.286	0.043	7.440	0.008
	Control group	30	26.57±2.22	27.43±2.26
RBANS	Research group	30	83.47±18.07	95.73±15.45	74.217	0.000	4.069	0.048	54.116	0.000
	Control group	30	80.87±15.10	81.83±15.68

Item	Group	n	Point of time		Time		Group		Time × Group
Item	Group	n	Before intervention （0 week）/score	After intervention（10 week）/score	F value	P value	F value	P value	F value	P value
PANSS： positive	Research group	30	11.40±4.65	11.10±4.24	3.976	0.051	0.010	0.920	0.131	0.718
	Control group	30	11.33±5.71	10.90±5.81
PANSS： negative	Research group	30	23.90±5.01	18.20±4.24	82.129	0.000	4.901	0.031	86.063	0.000
	Control group	30	23.60±4.62	23.67±4.81
PANSS： commonly	Research group	30	31.40±6.12	29.70±5.72	17.452	0.000	0.523	0.473	1.652	0.204
	Control group	30	32.20±7.29	31.30±6.90
PANSS： total score	Research group	30	66.70±12.19	59.00±11.31	52.905	0.000	1.229	0.272	27.234	0.000
	Control group	30	67.13±14.21	65.87±13.95
MMSE	Research group	30	27.07±2.16	28.93±1.08	55.596	0.000	4.286	0.043	7.440	0.008
	Control group	30	26.57±2.22	27.43±2.26
RBANS	Research group	30	83.47±18.07	95.73±15.45	74.217	0.000	4.069	0.048	54.116	0.000
	Control group	30	80.87±15.10	81.83±15.68

[1]	Meng-ting SHEN, Xuan-hong ZHANG, Zhen-ying QIAN, Hui LI, Jian-hua SHENG, Ji-jun WANG, Ying-ying TANG. Comparison of mismatch negativity in patients with schizophrenia and depression [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1041-1045.
[2]	Yi WANG, Cheng CHENG, Hong-yan SHEN, Hong-yan GAO, Yue-ning DAI, Zheng-hui YI. Meta-analysis of efficacy of transcranial magnetic stimulation for the treatment of cognitive function and behavioral and psychological symptoms of dementia in patients with Alzheimer′s disease [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 931-941.
[3]	Hong-yan XUAN, Li-hua WANG, Hua-fang LI. Review of the factors influencing bone metabolism in schizophrenia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 972-976.
[4]	Bing-fu SONG, Bin-bin Ding, Xiao-li ZHANG, Li-yun YAO. Observation of therapeutic efficacy of metformin on glucose dysregulation and dyslipidaemia induced by quetiapine in patients with schizophrenia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 776-780.
[5]	Guo-qin HU, Cheng-qing YANG, Qin-yu LÜ, Jing ZHAO, Ming-huan ZHU, Zheng-hui YI, Xin-hai DAI. Effects of computerized cognitive correction therapy on cognitive function of schizophrenia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 622-627.
[6]	Wen-jun HUANG, Su-su JIANG, Min-fang TAO. Correlation between sleep quality and everyday cognitive function in perimenopausal and postmenopausal women [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(4): 497-501.
[7]	Rui LI, Duan ZENG, Shen HE, Yi-feng SHEN, Hua-fang LI. Association study of HRAS proto-oncogene single nucleotide polymorphism with schizophrenia and therapeutic response to atypical antipsychotics [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1613-1617.
[8]	Nuo-shi QIAN, Wu HONG, Chun-bo LI. Progress of transcranial direct current stimulation in the treatment of children and adolescents psychiatric disorders [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(10): 1366-1370.
[9]	Hong YANG, Xin-xin HUANG, Chao LIU, Qing-song LIANG, Hua YANG, Jian-biao ZHANG, Jian XU, Ying-yi WANG, Hai-su WU, Qin-yu LÜ, Zheng-hui YI. Association study of synaptotagmin 2 gene polymorphisms with schizophrenia in Chinese Han population [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 16-22.
[10]	Guo-qin HU, Qin-yu LÜ, Jing ZHAO, Ming-huan ZHU, Shun-ying YU, Zheng-hui YI, Jian CHEN. Association study of non-coding variant of NOS1AP gene with schizophrenia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 29-34.
[11]	LUAN Feng-huan, YE Hui-ling, XU Lu, FAN Qing, SONG Li-sheng. Application of social skills training to outpatients with schizophrenia [J]. , 2020, 40(4): 500-.
[12]	LI Na, AN Yu, ZHANG Yong-lu, DING Zhi-jie, WU Bai-lin, LAN Xiao-ping. Association analysis of single nucleotide polymorphisms in the promoter region of GAD1 and GABRB3 with schizophrenia in Chinese Han population [J]. , 2020, 40(3): 310-.
[13]	LI Xuan, XIANG Qiong, ZHAN Yan, ZHU Dian-ming, ZHUO Kai-ming, WANG Ya, CHEN Hai-ying, LIU Deng-tang. Psychological mechanism of event-based prospective memory deficit in patients with first-episode schizophrenia [J]. , 2020, 40(2): 208-.
[14]	WEN Wan-jun1, CHEN Ye1, QIN Zong-hou1, LÜ Wang-qiang2, TANG Wei3, LU Wei-hong4, FAN Wei-xing2, ZHANG Chen4. Relationship between serum interleukin-6 level and depressive symptoms in schizophrenia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1618-1620.
[15]	REN Yan-yan, LÜ Qin-yu, YANG Wei-li, WANG Zhen. Correlation between childhood trauma and schizophrenia symptoms [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1641-1645.